SEC Filing Summary: OXIS International, Inc. (10-Q)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2009, for OXIS International, Inc. (Note: The input metadata referenced "GT Biopharma," but the filing text explicitly identifies the registrant as OXIS International, Inc.). The Company is a smaller reporting company focused on the development of nutraceutical and therapeutic products targeting oxidative stress, specifically utilizing patents for Ergothioneine. The Company sold its assay business division in December 2008 and is currently in a pre-revenue stage for its new product focus.
Key Financial Metrics
| Metric | Q3 2009 (3 Months) | YTD 2009 (9 Months) | YTD 2008 (9 Months) |
|---|---|---|---|
| Total Revenue | $0 | $35,000 | $992,000 |
| Net Loss | $(268,000) | $(909,000) | $(4,424,000) |
| Cash and Equivalents (End of Period) | $0 | $0 | $31,000 |
| Total Assets | $589,000 | $589,000 | $590,000 |
| Total Liabilities | $5,178,000 | $5,178,000 | $4,270,000 |
| Stockholders' Deficit | $(4,589,000) | $(4,589,000) | $(3,680,000) |
| Accumulated Deficit | $(75,763,000) | $(75,763,000) | $(74,854,000) |
Liquidity & Debt: The Company had zero cash on hand as of September 30, 2009. Current liabilities include $2,123,000 in convertible debentures, $532,000 in derivative liabilities, and $171,000 in demand notes (net of discount). The Company is in default on monthly redemption payments for its 2006 debentures.
Material Changes vs. Prior Period
- Revenue Collapse: Product revenues dropped to $0 for the quarter and $35,000 for the nine months ended September 30, 2009, compared to $315,000 and $992,000 in the same periods of 2008. This decline is attributed to the sale of the assay kit division in December 2008.
- Reduced Net Loss: The net loss for the nine months ended September 30, 2009 ($909,000) was significantly lower than the prior year ($4.4 million). The 2008 loss was heavily impacted by a $2.7 million loss on the disposition of discontinued operations and higher interest expenses related to penalty interest on defaulted debentures.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased by $667,000 year-over-year (9 months), driven by reduced non-cash compensation, overhead, and staff reductions. R&D expenses also decreased.
- Derivative Liability Increase: The derivative liability increased from $174,000 at year-end 2008 to $532,000 at September 30, 2009, resulting in a $94,000 expense for the period due to fair value adjustments.
Outlook, Risks, and Unusual Items
- Going Concern Warning: Management explicitly states that the current rate of cash usage raises "substantial doubt" about the Company's ability to continue as a going concern. The Company has no cash and requires additional equity or debt financing to sustain operations.
- Subsequent Financing: On October 1, 2009 (post-period), the Company entered into a financing arrangement for up to $2,000,000 in convertible debentures and warrants. Proceeds are held in escrow pending settlement with existing creditors.
- Debt Default & Forbearance: The Company is in default on its October 2006 debentures (34 months behind on payments as of Nov 2009). However, a Standstill and Forbearance Agreement was signed with a major creditor (Bristol Investment Fund) in October 2009, temporarily halting foreclosure actions.
- Internal Control Weaknesses: The Company disclosed material weaknesses in internal controls, noting that all accounting and financial reporting operations are performed by a single individual, creating a risk of undetected material misstatements.
- Unusual Items: The 2008 period included a significant loss on the disposal of discontinued operations ($2.7 million), which is not present in the 2009 period.
Investor Verification Checklist
- Cash Runway: Verify the status of the October 2009 financing escrow and whether funds have been released to the Company to cover operating expenses.
- Debt Settlement: Confirm the terms of the settlement with existing creditors (specifically Bristol Investment Fund) regarding the defaulted 2006 debentures and the $2.6 million deficiency.
- Product Pipeline: Assess the commercial viability and regulatory status of the Ergothioneine-based nutraceutical products, as the Company has no current revenue stream.
- Dilution Risk: Review the terms of the new $2 million debentures and the extensive warrant overhang (over 53 million warrants outstanding) which could significantly dilute existing shareholders upon conversion.
- Internal Controls: Evaluate the Company's plan to remediate the material weakness regarding the single-person accounting function.